SURVEY How do you feel about Elon Musk's alliance with Donald Trump? Take our poll. HKSE - Delayed Quote ? HKD Alphamab Oncology (9966.HK) Follow Compare 3.740 -0.100 (-2.60%) At close: 4:08 PM GMT+8 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Exploring High Growth Tech Stocks In Hong Kong As global markets experience shifts with interest rate adjustments and economic indicators showing mixed signals, the Hong Kong market remains a focal point for investors seeking opportunities in high-growth tech sectors. In this dynamic environment, identifying promising stocks often involves assessing companies that not only demonstrate robust innovation and adaptability but also align well with prevailing market trends and economic conditions. Simply Wall St. ? yesterday 9966.HK -2.60% XDNCF 2315.HK IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combined with albumin-bound Docetaxel HB1801 has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer. PR Newswire ? 5 days ago 9966.HK -2.60% Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of Alphamab Oncology ("the Company"), entered into a licensing agreement (the "Licensing Agreement") on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK). PR Newswire ? 22 days ago 9966.HK -2.60% High Growth Tech Stocks To Watch In Hong Kong This September 2024 As global markets show signs of recovery with technology stocks leading the charge, Hong Kong's tech sector remains a focal point for investors seeking high growth opportunities. Amidst this dynamic landscape, identifying promising tech stocks involves evaluating their innovation potential, market position, and resilience to economic fluctuations. Simply Wall St. ? last month 3393.HK 2315.HK 9966.HK -2.60% Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona, Spain. Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors. PR Newswire ? last month 9966.HK -2.60% Top 3 High Growth Tech Stocks In Hong Kong To Watch As global markets show signs of optimism, with the Hang Seng Index up 1.99% and technology stocks leading gains, Hong Kong's tech sector is drawing significant investor attention. In this dynamic environment, identifying high-growth tech stocks requires a keen eye on companies that are not only innovating but also demonstrating strong fundamentals and market adaptability. Simply Wall St. ? last month 2315.HK 9966.HK -2.60% 3393.HK Alphamab Oncology Reports 2024 Interim Results and Business Highlights Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2024 and highlighted recent business progress. PR Newswire ? 2 months ago 9966.HK -2.60% Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 in patients with platinum-resistant ovarian cancer and patients with advanced HER2-positive (IHC 3+) solid tumors, will be presented as posters at the 2024 European Society for Medical Oncology Congress (ESMO Congress 2024) from September 13 to 17, 2024, in Barcelona, Spain. PR Newswire ? 2 months ago 9966.HK -2.60% ArriVent partners Alphamab to develop ADCs for cancer ArriVent will pay up to $615.5m in combined upfront and potential milestone payments to Alphamab. Pharmaceutical Technology ? 4 months ago ^YH206 Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products Alphamab Oncology (stock code: 9966.HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and collaboration agreement (the "Collaboration Agreement") with ArriVent BioPharma, Inc., the shares of which are listed on the Nasdaq Global Market (ticker symbol: AVBP) ("ArriVent"), pursuant to which, Alphamab and ArriVent will collaborate to use Alphamab's proprietary linker-payload (Alphatecan) and glycan-conjug PR Newswire ? 4 months ago 9966.HK -2.60% Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, were presented for the first time at the 2024 Annual Meeting of American Society of Clinical Oncology (2024 ASCO Annual Meeting). PR Newswire ? 4 months ago 9966.HK -2.60% Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016 Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, in the treatment of Chinese patients with advanced malignant solid tumors. PR Newswire ? 4 months ago 9966.HK -2.60% Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presented for the first time at the 2024 Annual Meeting of American Society of Clinical Oncology (2024 ASCO Annual Meeting) from May 31 to June 4, 2024, in Chicago, IL, U.S.. PR Newswire ? 5 months ago 9966.HK -2.60% Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR Alphamab Oncology (stock code: 9966.HK) announced the data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, were presented as a poster at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024). PR Newswire ? 6 months ago 9966.HK -2.60% Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and highlighted recent progress and upcoming milestones. PR Newswire ? 6 months ago 9966.HK -2.60% Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033 Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed in Australia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody, for the treatment of HER2-expressing, advanced or metastatic solid tumors. PR Newswire ? 6 months ago 9966.HK -2.60% The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published online in the renowned journal Cell Reports Medicine (IF: 14.3). Professor Li Zhang from Sun Yat-Sen University Cancer Center is the corresponding author of this paper, and Professor Yuanyuan Zhao is the first author. PR Newswire ? 6 months ago 9966.HK -2.60% Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024 Alphamab Oncology (stock code: 9966.HK) announced that data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, has been accepted by the American Association for Cancer Research Annual Meeting 2024 (AACR 2024) and the results will be presented as a poster. PR Newswire ? 7 months ago 9966.HK -2.60% The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications Alphamab Oncology (stock code: 9966.HK) announced that the phase Ⅱclinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel as first-line treatment in advanced triple-negative breast cancer (TNBC) were published online in the renowned journal Nature Communications (IF: 16.6, JCR Q1). Professor Binghe Xu from Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College is the corresponding author of this paper. PR Newswire ? 8 months ago 9966.HK -2.60% Alphamab Oncology and 3DMedicines Entered into a Licensing Agreement with Glenmark for KN035 Alphamab Oncology (stock code: 9966.HK) and 3DMedicines (stock code: 1244.HK) ("Licensors") announced that we entered into a license agreement with Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296，NSE: GLENMARK) for the subcutaneous injection PD-L1 antibody drug (R&D code: KN035, generic name: Envafolimab), pursuant to which, Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology indications in India, PR Newswire ? 8 months ago 9966.HK -2.60% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 9966.HK HANG SENG INDEX YTD -43.67% +20.25% 1-Year -60.96% +19.37% 3-Year -79.13% -21.21%
